01—Abstract
Summary
Summary of the 10-K filed February 25, 2008. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. (filed under the name Exelixis, Inc.) reported a 2007 net loss of $86.4 milliona, compared with $101.5 million in 2006, on total revenues of $113.5 million, up from $98.7 million.
Research and development expenses rose to $225.4 millionb from $185.5 million, and general and administrative expenses to $44.9 million from $39.1 million. The improvement in net loss was driven largely by non-recurring gains of $18.8 million on the sale of its plant trait business to Dow/Agrigenetics and $18.1 million on the sale of 80.1% of its German subsidiary, Artemis Pharmaceuticals GmbH. Management expects losses in 2008 to increase relative to 2007 and expects negative operating cash flow for the foreseeable future.
At December 31, 2007, the company had $299.5 millionc in cash, cash equivalents and marketable securities, including $30.9 million held by Symphony Evolution, Inc. (SEI) and $7.2 million of restricted cash and investments. Management states these resources will fund operations for at least 12 months following the filing date. Stockholders' equity was $72.1 million, and the accumulated deficit was $791.7 million.
The company's GlaxoSmithKline loan covenants require working capital of at least $25.0 milliond and cash and investments of at least $50.0 million; the filing reports $150.9 million and $292.3 million respectively at year-end. The pipeline is concentrated in oncology, with eleven clinical-stage cancer compounds, led by XL647 (Phase 2, out-licensed to SEI), XL880 (Phase 2, option exercised by GlaxoSmithKline in December 2007) and XL820 (Phase 2).
The filing highlights that GlaxoSmithKline declined to exercise its option on XL647 and XL784, and that XL999 was discontinued after cardiac adverse events. Revenue is almost entirely collaboration-based, with Bristol-Myers Squibb (35%), GlaxoSmithKline (24%), Genentech (16%) and Daiichi-Sankyo (10%) accounting for the largest shares in 2007.
02—Key points
Key Highlights
- Total revenues rose to $113.5 million in 2007 from $98.7 million in 2006, with the filing attributing the growth primarily to license and contract revenues.
- Net loss narrowed to $86.4 million (or $0.87 per share) from $101.5 million in 2006, helped by $36.9 million in combined gains on the sale of the plant trait business and 80.1% of Artemis Pharmaceuticals GmbH.
- Research and development expenses increased to $225.4 million from $185.5 million, driven by clinical trial activity, personnel and lab supplies.
- Cash, cash equivalents and marketable securities totaled $299.5 million at December 31, 2007, which management says will fund operations for at least 12 months after the filing date.
- The company expects its 2008 losses to increase compared with 2007 and anticipates negative operating cash flow for the foreseeable future.
- The XL647, XL784 and XL999 programs are out-licensed to Symphony Evolution, Inc., with a repurchase option exercisable until June 9, 2009 at a price that increases 25% per year on funded capital; GlaxoSmithKline declined to exercise development options on XL647 and XL784, and XL999 was discontinued in December 2007.
- The GlaxoSmithKline loan of $98.6 million carries financial covenants on working capital and cash and investments, and the filing reports the company in compliance as of December 31, 2007.
03—Questions
Frequently Asked Questions
Why did the net loss decline in 2007 despite higher spending?
The filing attributes the narrower loss mainly to non-recurring gains: $18.8 million from selling the plant trait business to Agrigenetics (a Dow subsidiary) and $18.1 million from selling 80.1% of Artemis Pharmaceuticals GmbH. Revenue growth of $14.8 million also contributed, while research and development expense rose $39.9 million.
How much cash does the company have and how long will it last?
The company had $299.5 million in cash, cash equivalents, marketable securities and restricted investments at December 31, 2007, including $30.9 million held by SEI. Management anticipates these resources, plus expected collaborator funding and assuming a moderate level of business development activity, will support operations for at least 12 months after the filing date. The filing warns that future capital needs could require using capital earlier than anticipated.
Who are the company's main revenue sources?
In 2007, Bristol-Myers Squibb accounted for 35% of revenues, GlaxoSmithKline 24%, Genentech 16% and Daiichi-Sankyo 10%. The filing notes that substantially all revenue to date has come from collaborative research and development agreements, and that the company has not yet generated product revenue from pharmaceutical sales.
What are the key pipeline developments and risks?
The company lists eleven cancer compounds in clinical development. XL880 was selected by GlaxoSmithKline in December 2007, with the program expected to transfer in the first quarter of 2008. XL139 was selected by Bristol-Myers Squibb in January 2008. XL999 was discontinued after cardiac adverse events, and GlaxoSmithKline declined options on XL647 and XL784. The filing also notes that the company has no approved products and that clinical trial results may not support regulatory approval.
What obligations could affect the company's finances?
Total contractual cash obligations were $308.7 million, including $172.0 million of operating leases and $98.6 million of convertible loans (including interest) owed to GlaxoSmithKline. If the company exercises its option to repurchase XL647, XL784 and XL999 from SEI, it would need to pay the capital invested of $80.0 million plus 25% per year, in cash or shares. The filing also notes that the company will need to pay 35% of worldwide development expenses for XL139 following its co-development election.
04—Continue